UNITED STATES
                         SECURITIES EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                   FORM 10-QSB


[X]   Quarterly  Report  pursuant  to  Section  13 or  15(d)  of the  Securities
      Exchange Act of 1934

                For the quarterly period ended November 30, 2003


                               BIOACCELERATE INC.
             (Exact name of registrant as specified in its charter)


                               BIOACCELERATE INC.
             (Exact name of registrant as specified in its charter)


          DELAWARE                                        13-4032994
          --------                                        ----------
(State or other jurisdiction                          (I.R.S. Employer
of incorporation or organization)                     Identification No.)

16th Floor, 666 Third Avenue
New York, NY                                                  10017
----------------------------------------                   ----------
(Address of principal executive offices)                   (Zip Code)


                   Registrant's telephone number 212 697 1978


 As of February 9, 2003, the following shares of the Registrant's common stock
                          Were issued and outstanding:

                    22,781,014 shares of voting common stock

<PAGE>


INDEX

PART I - FINANCIAL INFORMATION


Item 1.   Financial Statements . . . . . . . . . . . . . . . . .3
          CONDENSED CONSOLIDATED BALANCE SHEET . . . . . . . . .4
          CONDENSED CONSOLIDATED INCOME STATEMENT. . . . . . . .5
          STATEMENT OF CASH FLOWS. . . . . . . . . . . . . . . .6
          Note 1.   NATURE OF BUSINESS AND SIGNIFICANT
                    ACCOUNTING POLICIES. . . . . . . . . . . . .8
          Note 2.   USE OF OFFICE SPACE. . . . . . . . . . . . .8
          Note 3.   EARNINGS PER SHARE . . . . . . . . . . . . .9
          Note 4.   LIQUIDITY . . . . . . . . . . . . . . . . . 9
          Note 5.   CONTRIBUTED SERVICES . . . . . . . . . . . .9
          Note 6.   SUBSEQUENT EVENTS . . . . . . . . . . . . . 9

Item 2.   Management's Discussion And Analysis or Plan of
          Operations. . . . . . . . . . . . . . . . . . . . . .11

PART II - OTHER INFORMATION

Item 1.   Legal Proceedings. . . . . . . . . . . . . . . . . . 16

Item 2.   Changes in Securities. . . . . . . . . . . . . . . . 16

Item 3.   Defaults upon Senior Securities. . . . . . . . . . . 16

Item 4.   Submission of Matters to a Vote of
          Security Holders . . . . . . . . . . . . . . . . . . 16

Item 5.   Other information. . . . . . . . . . . . . . . . . . 15

Item 6.   Exhibits and Reports on Form 8-K . . . . . . . . . . 16


SIGNATURES . . . . . . . . . . . . . . . . . . . . . . . . . . 17





                                        2


<PAGE>


                         PART I - FINANCIAL INFORMATION

                               BIOACCELERATE, INC.
                          (A Development Stage Company)
                      CONDENSED CONSOLIDATED BALANCE SHEET


                                                      As Of            As Of
                                                November 30, 2003   May 31, 2003
                                                  (Unaudited)       (Audited)
                                                -----------------   ------------
ASSETS
Current Assets
Cash & cash Equivalents                             $ 1,405,000               0
Investments                                              10,868     $         0
Goodwill                                                988,698               0
                                                    -----------     -----------
TOTAL ASSETS                                        $ 2,404,566     $         0

LIABILITIES AND SHAREHOLDERS' EQUITY

Current Liabilities
Accounts Payable                                    $    61,600     $         0

Accrued Expenses                                              0          52,406
                                                    -----------     -----------
Total Current Liabilities                                61,600          52,406

Other Liabilities
 Loan Payable - European Technology
 Investments Ltd - Note 6                                     0          71,950
                                                    -----------     -----------
Total Liabilities                                   $    61,600     $   124,356

Stockholders' Equity
 Common Stock, $.001 par value,
 Authorized 25,000.000 Shares;
 Issued and Outstanding
 19,000,000 Shares                                       19,625           5,000
Additional Paid in Capital                            1,994,055         410,045
Deficit Accumulated During the
Development Stage                                      (625,714)       (539,401)
                                                    -----------     -----------

Total Stockholders' Equity                            2,342,966        (124,356)

TOTAL LIABILITIES AND
 STOCKHOLDERS' EQUITY                               $ 2,404,566     $         0



The accompanying notes and accountant's report are an integral part of these
financial statements.

                                        3


<PAGE>


                               BIOACCELERATE, INC.
                          (A Development Stage Company)
                CONDENSED CONSOLIDATED STATEMENT OF INCOME (LOSS)



                                                  For the           For the
                                                3 Mos Ended       3 Mos Ended
                                             November 30 2003   November 30,2002
                                             ----------------   ----------------

TOTAL REVENUES:                                $          0      $          0

OPERATING EXPENSES:
 Accounting                                          30,000             1,750
 Legal                                               25,000             2,500
 Rent (Note 3)                                        6,600             1,200
Filing Fee                                                0                13
Contributed Services
       (Note 5)                                           0            17,500
                                               ------------      ------------
Total Operating Expenses                             61,600            22,963

Operating Loss                                 $    (61,600)          (22,963)

NET LOSS                                            (61,600)          (22,963)


NET LOSS PER SHARE                                    (.003)             (.00)

Weighted Average
  Number of Shares
  Outstanding                                    19,625,000         5,000,000



The accompanying notes and accountant's report are an integral part of these
financial statements.

                                        4


<PAGE>


                               BIOACCELERATE, INC.
                          (A Development Stage Company)
                       STATEMENT OF CASH FLOWS (UNEDITED)



CASH FLOWS FROM OPERATING
ACTIVITIES:
                                               For the 3 mos    For the 3 mos
                                                   Ended            Ended
                                             November 30,2003  November 30,2002
                                             ----------------  ----------------

Net Loss                                          $(61,600)      $(22,963)

Adjustments to Reconcile Net Loss
to Net Cash Used in operating
Activities:
 Additional Paid in Capital
 Contributed by Shareholders for:
    Rent                                                 0            600
    Contributed Services                                00         17,500

Increase / Decrease in Accounts Payable
 and Accrued Expenses                               61,600         (5,737)
                                                  --------       --------

Total Adjustments                                 $ 61,600       $ 12,363
Net Cash Used in
Operating Activities                                     0        (10,600)


CASH FLOWS FROM FINANCING
ACTIVITIES:

Increase in Loan Payable -
 European Tech Investments Ltd                           0        (10,600)
                                                  --------       --------
Net Cash Provided
by Financing Activities                                  0         10,600

Net Change in Cash                                       0              0

Cash at Beginning of Period                              0              0
Cash at End of Period                             $      0              0

Supplemental Disclosure of
Cash Flow Information
Cash Paid During the Period for

Interest Expense                                         0              0
Corporate Taxes                                   $      0              0


The accompanying notes and accountant's report are an integral part of these
financial statements.

                                        5


<PAGE>


                               BIOACCELERATE, INC.
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                                NOVEMBER 30, 2003

NOTE 1 - NATURE OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES

A. DESCRIPTION OF COMPANY: Bioaccelerate Inc., ("the Company") is a for-profit
corporation incorporated under the laws of the State of Delaware on December 29,
1995 as Tallman Supply Corp. On January 14, 1999 the Company changed its name to
Westminster Auto Retailers Inc. On December 10, 2002 the Company changed its
name to Westminster Medical Inc. On July 25, 2003 the Company changed its name
to Bioaccelerate Inc.

The Company is a development stage company and the directors focusing on
opportunities both start ups and developing companies in the biopharmaceutical
sector. On 31st August 2003 the holders of Common stock agreed to a 5 for 1
reverse of the issued shares capital. This had the effect of reducing the Common
stock from 5million shares to 1million shares.
 The Company entered into a letter of intent to acquire Pharma Manufacturing
Services Limited during the quarter ending 31st August 2003 and the acquisition
was completed on September 1st 2003 by the issue of 18,000,000 post reverse
split shares of Common Stock.

Pharma Manufacturing Services Limited (PMSL) is a company that acquires and
develops pharmaceutical assets, both corporate and physical. It currently has
equity interests in 8 Biopharmaceutical companies. PMSL was formed to take
advantage of the burgeoning biopharmaceutical marketplace and has a niche in the
creation of shareholder value through the development of compounds and also the
companies that will commercialize those compounds. The Companies in which it
currently has equity interests focus on five medical areas, being Cancer,
Cardiovascular, Lifestyle, Central Nervous System, and Anti-viral, areas with a
current combined market value of $200 billion.


NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES

A. BASIS OF PRESENTATION: Financial statements are prepared on the accrual basis
of accounting. Accordingly revenue is recognized when earned and expenses when
incurred.

B. USE OF ESTIMATES: The preparation of financial statements in conformity with
generally accepted accounting principles requires management to make estimates
and assumptions that affect certain reported amounts and disclosures.
Accordingly, actual results could differ from these estimates. Significant
estimates in the financial statements include the assumption that the Company
will continue as a going concern. See Note 4.

C. the Company has investments in developing technology companies. The valuation
of these investments is based on a company's share price discounted, if shares
are restricted, in relation to the period remaining before the shares can be
traded freely.

NOTE 3 - USE OF OFFICE SPACE

The Company uses office space for its executive offices at two locations. The
fair market value of the 600 square foot office at 32 Haymarket, London, UK is
$2000 per month. The fair market value of the 400 square foot office at 666
Third Avenue 16th Floor New York is $200 per month.


                                        6

<PAGE>


NOTE 4 - LIQUIDITY

The Company's viability as a going concern is dependent upon raising additional
capital, and ultimately, having net income. The Company's limited operating
history, including its losses and no revenues, primarily reflect the operations
of its early stage. As a result, the Company had from time of inception to
November 30, 2003 no revenue and a net loss from operations of $625,714.

The Company requires additional capital principally to meet its costs for the
implementation of its business plan, for general and administrative expenses and
to fund costs associated with its further development. It is not anticipated
that the Company will be able to meet its financial obligations through internal
net revenue in the near term. Bioaccelerate, Inc. does not have a working
capital line of credit with any financial institution. Therefore, future sources
of liquidity will be limited to the Company's ability to obtain additional debt
or equity funding. See Note 6.


NOTE 5- LOAN PAYABLE (EUROPEAN TECHNOLOGY INVESTMENTS LIMITED)

As of November 30, 2003, European Technology Investments Limited has paid
$71,950 of expenses on behalf of Bioaccelerate, Inc. The loan was not evidenced
by a note and the agreement called for no payment of interest. Under an
agreement with the creditors (see note 7) this loan has now been exchanged for
Common stock in Bioaccelerate, Inc.


NOTE 7 - NON-CASH FINANCIAL TRANSACTIONS

Non-cash financing transactions consisting of the cost of contributed services,
contributed rent and the related additional paid in capital contributed by
shareholders have been included in expenses and additional paid in capital,
respectively, in earlier financial statements. Following the acquisition of PMSL
the creditors in that company and the creditors of Bioaccelerate Inc agreed to
accept post split common stock to the value of their outstanding invoices. This
resulted in the issue of a further 625,014 shares of Common stock.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION AND RESULTS OF
OPERATIONS

The Company up until November 30, 2003 was a development stage company and its
principal business purpose was to develop assets in the pharmaceutical industry.

The Financial Statements filed in Item 1 of this 10QSB filing, reflect the
financial condition of the company as at the end of its last fiscal year at 31st
May 2003 and the subsequent six month period.

The Company filed a Form 8-K on September 19,, 2003 reporting that the company
had acquired UK based Pharma Manufacturing Services Limited. An amendment to
form 8-K was filed on November 28, 2003 which included the required financial
statements of Pharma Manufacturing Services Limited.

Pharma Manufacturing Services Limited (PMSL) is a company that acquires and
develops pharmaceutical assets, both corporate and physical. It currently has
equity interests in 8 Biopharmaceutical companies. PMSL was formed to take
advantage of the burgeoning biopharmaceutical marketplace and has a niche in the
creation of shareholder value through the development of compounds and also the
companies that will commercialize those compounds. The Companies in which it
currently has equity interests focus on five medical areas, being Cancer,
Cardiovascular, Lifestyle, Central Nervous System, and Anti-viral, areas with a
current combined market value of $200 billion.


REVENUE

For the six month period ended November 30, 2003, the Company had no revenue.

OPERATING EXPENSES

During the three month period ending November 30, 2003 we incurred $61,600 of
operating expenses, as compared to $22,963 for the three month period ended
November 30, 2002. This increase was mostly due to increased legal and
accounting costs incurred in preparation for fund raising.


<PAGE>


NET LOSS

Our net loss for the three month period ending November 30, 2003 was $61,600 as
compared to a net loss for the three month period ending November 30, 2002 of
$22,963.

LIQUIDITY AND CAPITAL RESOURCES

To date, we have incurred significant and increasing net losses. In the event
that our current business plan does not meet expectations we anticipate that we
may continue to incur significant operating losses.

We have an accumulated deficit of $625,714 as at November 30, 2003. We plan to
meet our working capital needs and finance our growth plan during the coming
fiscal year through a combination of financing, equity capital and the possible
realization of assets in the Company's holdings. There can be no assurance as to
whether or when we will generate material revenues or achieve profitable
operations.
We have insufficient relevant operating history upon which an evaluation of our
performance and prospects can be made. We are still subject to all of the
business risks associated with a new enterprise, including, but not limited to,
risks of unforeseen capital requirements, lack of fully-developed products,
failure of market acceptance, failure to establish business relationships,
reliance on outside contractors for the manufacture and distribution, and
competitive disadvantages against larger and more established companies. The
likelihood of our success must be considered in light of the development cycles
of new products and technologies and the competitive environment in which we
operate.

The Company's viability as a going concern is dependent upon raising additional
capital, and ultimately, having net income. Our limited operating history,
including our losses, primarily reflects the operations at this early stage in
its development.

Before our operating plan can be effected, we will require additional financing.
Furthermore, in the event our plans change or our assumptions change or prove to
be inaccurate, we could be required to seek additional financing sooner than
currently anticipated. Any additional financing may not, however, be available
to us when needed on commercially reasonable terms, or at all. If this were to
occur, our business and operations would be materially and adversely affected.

Based on our operating plan, we are seeking arrangements for long-term funding
through additional capital raising activities. The Company is actively reviewing
various avenues to raise finance and we are currently visiting with and meeting
a number of potential investors.

                           PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

There are currently no pending legal proceedings against the company.

ITEM 2. CHANGES IN SECURITIES

There has been no change in the Company's securities.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

There has been no default in the payment of principal, interest, sinking or
purchase fund installment.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

No matter has been submitted to a vote of security holders during the period
covered by this report.

ITEM 5. EXHIBITS AND REPORTS ON FORM 8-K

A form 8-K/A was filed on November 28, 2003 which is hereby incorporated by
reference.

Exhibit
10.1
10.2
99.1
99.2

<PAGE>


                                   SIGNATURES

Pursuant to the requirements of Section 12 of the Securities Exchange Act of
1934, the registrant has duly caused this registration statement to be signed on
its behalf by the undersigned, thereunto duly authorized.

BIOACCELERATE INC
----------------------
(Registrant)
Date: October 15, 2003

                                                By: /s/ B.R. Parker
                                                    -----------------
                                                    President

<PAGE>


                                 CERTIFICATIONS

                         I, Basil Parker, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of Bioaccelerate Inc;

2. Based on my knowledge, this annual report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this annual
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this annual report;

4. The registrant's other certifying officers and I am responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this annual report is being prepared;

b) evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this annual
report (the "Evaluation Date"); and

c) Presented in this annual report our conclusions about the effectiveness of
the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):

a) all significant deficiencies in the design or operation of internal controls
which could adversely affect the registrant's ability to record, process,
summarize and report financial data and have identified for the registrant's
auditors any material weaknesses in internal controls; and

b) Any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officers and I have indicated in this
annual report whether or not there were significant changes in internal controls
or in other factors that could significantly affect internal controls subsequent
to the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.

Date: February 10, 2003

                                           /s/ Basil Parker
                                           -------------------------
                                           Basil Parker
                                           President & Director


<PAGE>


I, Linden Boyne, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of Bioaccelerate Inc;

2. Based on my knowledge, this annual report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this annual
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this annual report;

4. The registrant's other certifying officers and I am responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this annual report is being prepared;

b) evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this annual
report (the "Evaluation Date"); and

c) Presented in this annual report our conclusions about the effectiveness of
the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):

a) all significant deficiencies in the design or operation of internal controls
which could adversely affect the registrant's ability to record, process,
summarize and report financial data and have identified for the registrant's
auditors any material weaknesses in internal controls; and

b) Any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officers and I have indicated in this
annual report whether or not there were significant changes in internal controls
or in other factors that could significantly affect internal controls subsequent
to the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.

Date: February 10, 2003

                                                /s/ Linden Boyne
                                                -----------------------
                                                Linden Boyne
                                                Secretary and Director